<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39392769</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2471-254X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Hepatology communications</Title><ISOAbbreviation>Hepatol Commun</ISOAbbreviation></Journal><ArticleTitle>Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e0517</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/HC9.0000000000000517</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The impact of clinical factors and social determinants of health on treatment patterns and health care costs among patients with HCC is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using 100% Medicare Fee-For-Service claims and a commercial multipayor claims database, we identified patients diagnosed with HCC from January 1, 2017, to December 31, 2020. Surveillance receipt was defined 12 months prior to HCC diagnosis, whereas treatment and health care costs were assessed post-HCC diagnosis. Multinomial logistic regression was used to assess the association between demographics, social determinants of health, and surveillance or HCC treatment. Multivariable generalized linear regression was used to identify factors associated with total health care costs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 32,239 patients with HCC (mean age 68 y, 67% male, 73% White), 70% received surveillance and only half (51%) received any treatment. Curative treatment receipt was higher among those with prior surveillance (24% with CT/MRI and 18% with ultrasound vs. 9% with no surveillance). Curative treatment was independently associated with HCC surveillance and inversely associated with Black race, lower education level, and diagnosis in the year 2020 (COVID-19 year). Higher health care costs were independently associated with Black race, low English proficiency, living alone, and diagnosis in 2018-2020, and inversely associated with CT/MRI-based surveillance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Race and social determinants of health were independently associated with curative treatment receipt and health care costs. Increasing access to high-quality HCC surveillance may improve treatment receipt and reduce health disparities among patients with HCC.</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singal</LastName><ForeName>Amit G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Division of Digestive and Liver Disease, UT Southwestern Medical Center, Dallas, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilgore</LastName><ForeName>Karl M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-1103-2107</Identifier><AffiliationInfo><Affiliation>Inovalon Inc., Bowie, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shvets</LastName><ForeName>Elizabet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Avalere Health, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Neehar D</ForeName><Initials>ND</Initials><Identifier Source="ORCID">0000-0002-5874-9933</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan Medical School, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Neil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9476-468</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burak Ozbay</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8624-6313</Identifier><AffiliationInfo><Affiliation>Exact Sciences Corporation, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teigland</LastName><ForeName>Christie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Inovalon Inc., Bowie, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hafez</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Avalere Health, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Avalere Health, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Avalere Health, Washington, District of Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schinkel</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inovalon Inc., Bowie, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hepatol Commun</MedlineTA><NlmUniqueID>101695860</NlmUniqueID><ISSNLinking>2471-254X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064890" MajorTopicYN="Y">Social Determinants of Health</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Amit Singal has served as a consultant or on advisory boards for Genentech, AstraZeneca, Eisai, Bayer, Exelixis, Merck, Elevar, Boston Scientific, Sirtex, FujiFilm Medical Sciences, Exact Sciences Corporation, Universal Dx, Roche, Glycotest, Abbott, and GRAIL. Karl M. Kilgore, Christie Teigland, and Jill Schinkel are full-time employees of Inovalon Inc. who were paid consultants to support Exact Sciences Corporation in this study. Elizabet Shvets, Omar Hafez, Amy Schroeder, and Audrey Yang are full-time employees of Avalere Health who were paid consultants to support Exact Sciences Corporation in this study. Neehar D Parikh has served as a constultant of on advisory board for AstraZeneca, Eisai, Exelixis, Gilead, Fujifilm Medical Sciences, and Exact Sciences Corporation. A. Burak Ozbay is a full-time employee of Exact Sciences Corporation. The remaining author has no conflicts to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>18</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>18</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>13</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39392769</ArticleId><ArticleId IdType="pmc">PMC11469853</ArticleId><ArticleId IdType="doi">10.1097/HC9.0000000000000517</ArticleId><ArticleId IdType="pii">02009842-202411010-00002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">36633525</ArticleId></ArticleIdList></Reference><Reference><Citation>Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33479224</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari R, Sahu MK, Tripathy A, Uthansingh K, Behera M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepatic oncology. 2018;5:HEP08.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613045</ArticleId><ArticleId IdType="pubmed">31293776</ArticleId></ArticleIdList></Reference><Reference><Citation>SEER . Cancer of the Liver and Intrahepatic Bile Duct - Cancer Stat Facts. 2023. Accessed June 08, 2020. https://seer.cancer.gov/statfacts/html/livibd.html

</Citation></Reference><Reference><Citation>Rich NE, Yopp AC, Singal AG, Murphy CC. Hepatocellular carcinoma incidence is decreasing among younger adults in the United States. Clin Gastroenterol Hepatol. 2020;18:242–8.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817412</ArticleId><ArticleId IdType="pubmed">31042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021;15:1295–1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">34624198</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich NE, Murphy CC, Yopp AC, Tiro J, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;52:701–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7655123</ArticleId><ArticleId IdType="pubmed">32598091</ArticleId></ArticleIdList></Reference><Reference><Citation>McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 (Suppl 1):4–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7577946</ArticleId><ArticleId IdType="pubmed">32319693</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA, et al. . Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019;17:551–9.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6274621</ArticleId><ArticleId IdType="pubmed">29859983</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim AK, Singal AG. Health disparities in diagnosis and treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2015;4:143–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448755</ArticleId><ArticleId IdType="pubmed">30992943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagle NS, Park S, Washburn D, Ohsfeldt RL, Rich NE, Singal AG, et al. . Racial, ethnic, and socioeconomic disparities in curative treatment receipt and survival in hepatocellular carcinoma. Hepatol Commun. 2022;6:1186–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035560</ArticleId><ArticleId IdType="pubmed">34796703</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr. 2016;5:43–52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4739939</ArticleId><ArticleId IdType="pubmed">26904556</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephew LD, Gupta D, Carter A, Desai AP, Ghabril M, Patidar KR, et al. . Social determinants of health impact mortality from HCC and cholangiocarcinoma: A population-based cohort study. Hepatol Commun. 2023;7:e0058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9916098</ArticleId><ArticleId IdType="pubmed">36757397</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy SS, Ortiz A, DuBois T, Sorice KA, Nguyen M, Castellanos JA, et al. . The effect of social determinants of health on utilization of surgical treatment for hepatocellular carcinoma patients. Am J Surg. 2023;225:715–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">36344305</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Zhang X, Lu J, Liu S, Qian Y. Association between socioeconomic status and survival in patients with hepatocellular carcinoma. Cancer Med. 2021;10:7347–59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8525159</ArticleId><ArticleId IdType="pubmed">34414679</ArticleId></ArticleIdList></Reference><Reference><Citation>Seif El Dahan K, Reczek A, Daher D, Rich NE, Yang JD, Hsiehchen D, et al. . Multidisciplinary care for patients with HCC: A systematic review and meta-analysis. Hepatol Commun. 2023;7:e0143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10146543</ArticleId><ArticleId IdType="pubmed">37102768</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and meta-analysis. Hepatology. 2021;73:713–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648722</ArticleId><ArticleId IdType="pubmed">32383272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao A, Rich NE, Marrero JA, Yopp AC, Singal AG. Diagnostic and therapeutic delays in patients with hepatocellular carcinoma. J Natl Compr Canc Netw. 2021;19:1063–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">34077908</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal AG, Lok AS, Feng Z, Kanwal F, Parikh ND. Conceptual model for the hepatocellular carcinoma screening continuum: Current status and research agenda. Clin Gastroenterol Hepatol. 2022;20:9–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287785</ArticleId><ArticleId IdType="pubmed">32961340</ArticleId></ArticleIdList></Reference><Reference><Citation>MORE² Registry® Overview . Accessed May 30, 2023. https://www.inovalon.com/products/data-cloud/real-world-data/

</Citation></Reference><Reference><Citation>Acxiom Corporation 
(2020). ZIP+4 InfoBase® Geo Files: Demographic, Financial and Property, Sept 2019 release; Market Indices ACS, Feb 2019 release. Accessed May 30, 2023. https://www.acxiom.com
</Citation></Reference><Reference><Citation>Kilgore KM, McClellan M, Teigland C, Pulungan Z. Using aggregate data to proxy individual-level characteristics in health services research: 9-digit zipcode vs. census block group. Value in health 2018; 21: S218-9. (Poster presentation PRM50 at the ISPOR 23rd Annual International Meeting, Baltimore MD, May, 2018).</Citation></Reference><Reference><Citation>Danos D, Leonardi C, Gilliland A, Shankar S, Srivastava RK, Simonsen N, et al. . Increased risk of hepatocellular carcinoma associated with neighborhood concentrated disadvantage. Front Oncol. 2018;8:375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6141716</ArticleId><ArticleId IdType="pubmed">30254987</ArticleId></ArticleIdList></Reference><Reference><Citation>Rural-Urban Commuting Areas . US Dept. of Agriculture Economic Research Service. Accessed March 10, 2022. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes
</Citation></Reference><Reference><Citation>Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1607900</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VL, Singal AG, Tapper EB, Parikh ND. Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. Liver Int. 2020;40:947–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8047296</ArticleId><ArticleId IdType="pubmed">31943689</ArticleId></ArticleIdList></Reference><Reference><Citation>Brar G, Greten TF, Graubard BI, McNeel TS, Petrick JL, McGlynn KA, et al. . Hepatocellular carcinoma survival by etiology: A SEER-Medicare database analysis. Hepatol Commun. 2020;4:1541–1551. doi:10.1002/hep4.1564</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep4.1564</ArticleId><ArticleId IdType="pmc">PMC7527688</ArticleId><ArticleId IdType="pubmed">33024922</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobotka LA, Hinton A, Conteh LF. Insurance status impacts treatment for hepatocellular carcinoma. Ann Hepatol. 2019;18:461–465. doi:10.1016/j.aohep.2018.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aohep.2018.10.001</ArticleId><ArticleId IdType="pubmed">31040093</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, et al. . HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77:128–139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9232881</ArticleId><ArticleId IdType="pubmed">35139400</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal AG, Reddy S, Aka Patel HR, Villarreal D, Khan A, Liu Y, et al. . Multicenter randomized clinical trial of a mailed outreach strategy for hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2022;20:2818–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9184300</ArticleId><ArticleId IdType="pubmed">34902568</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. . AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10663390</ArticleId><ArticleId IdType="pubmed">37199193</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era? J Hepatology. 2023;78:207–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10229257</ArticleId><ArticleId IdType="pubmed">36089157</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoo T, Masaki N, Parikh ND, Lane BF, Feng Z, Mendiratta-Lala M, et al. . Multicenter validation of abbreviated MRI for detecting early-stage hepatocellular carcinoma. Radiology. 2023;307:e220917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10102624</ArticleId><ArticleId IdType="pubmed">36692401</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal AG, Tayob N, Mehta A, Marrero JA, El‐Serag H, Jin Q, et al. . GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022;75:541–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844059</ArticleId><ArticleId IdType="pubmed">34618932</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenberger H, Rich NE, Jones P, Yekkaluri S, Yopp A, Singal AG, et al. . Racial and ethnic disparities in barriers to care in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2023;21:1094–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9233716</ArticleId><ArticleId IdType="pubmed">34965448</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh ND, Tayob N, Al-Jarrah T, Kramer J, Melcher J, Smith D, et al. . Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort. JAMA network open. 2022;5:e2223504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9308050</ArticleId><ArticleId IdType="pubmed">35867057</ArticleId></ArticleIdList></Reference><Reference><Citation>Singal AG, Tiro JA, Murphy CC, Blackwell JM, Kramer JR, Khan A, et al. . Patient-reported barriers are associated with receipt of hepatocellular carcinoma surveillance in a multicenter cohort of patients with cirrhosis. Clin Gastroenterol Hepatol. 2021;19:987–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7779689</ArticleId><ArticleId IdType="pubmed">32629122</ArticleId></ArticleIdList></Reference><Reference><Citation>Taplin SH, Anhang Price R, Edwards HM, Foster MK, Breslau ES, Chollette V, et al. . Introduction: Understanding and influencing multilevel factors across the cancer care continuum. J Natl Cancer Inst Monogr. 2012;2012:2–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482968</ArticleId><ArticleId IdType="pubmed">22623590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagle NS, Park S, Washburn D, Ohsfeldt R, Kum HC, Singal AG. Racial and ethnic disparities in hepatocellular carcinoma treatment receipt in the United States: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2024;33:463–470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10990826</ArticleId><ArticleId IdType="pubmed">38252039</ArticleId></ArticleIdList></Reference><Reference><Citation>Mokdad AA, Zhu H, Marrero JA, Mansour JC, Singal AG, Yopp AC. Hospital volume and survival after hepatocellular carcinoma diagnosis. Am J Gastroenterol. 2016;111:967–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">27166130</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang DQ, Singal AG, Kono Y, Tan DJ, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell metabolism. 2022;34:969–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9762323</ArticleId><ArticleId IdType="pubmed">35793659</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim MA, Ramezani M, Leroux T, Kum HC, Singal AG. Healthcare costs for Medicare patients with hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol. 2023;21:2327–37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10205916</ArticleId><ArticleId IdType="pubmed">36435358</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>